Two referrals land on your desk on the same Monday morning. Helen is 62. David is 62.

One of them has stage II bowel cancer.
Both have had rectal bleeding and a change in bowel habit for six weeks. Neither wanted to do a FIT, so neither letter includes a result. Their referral letters read almost word for word the same. Without more data, there’s no way to tell which referral can’t wait.
This is an illustrative scenario. Helen and David are fictional.
What waiting on a colonoscopy costs Helen
Both patients go on the list as Category 1. That means a target of colonoscopy within 30 days. Suppose that target slips. It happens. Evidence from the UK shows what the slippage costs.
Loveday and colleagues modelled the effects of diagnostic delays of two, four and six months on the UK’s urgent suspect cancer referral pathway during the COVID pandemic [1]. Their cohort was more than 11,000 patients diagnosed through that route in a typical year [1].
The cost of waiting
Estimated deaths and life-years lost from diagnostic delay alone, in one year’s cohort of more than 11,000 patients on the UK urgent suspected cancer pathway.
| Delay | Attributable deaths | Life-years lost |
|---|---|---|
| 2 months | 653 | 9,214 |
| 4 months | 1,419 | 20,315 |
| 6 months | 2,250 | 32,799 |
A two-month delay caused an estimated 653 attributable deaths and 9,214 life-years lost [1].
At four months, deaths rose to 1,419, with 20,315 life-years lost [1].
At six months, deaths reached 2,250, with 32,799 life-years lost [1].
That’s from delay alone, in a single year’s cohort.
Helen’s cancer is stage II today. The longer she waits, the more likely it is to progress. And for stage III disease, a six-month delay cuts 10-year survival by more than 29% [1].
Takeaway: For Helen, every month on the list is a month in which her cancer can progress to a less treatable stage.
On paper, they look the same
You can’t tell Helen and David apart. Neither can anyone else. This is the core problem at scale.
Australians undergo around 1 million colonoscopies a year [2], and screening follow-up accounts for a small share of these: 4.7% in 2015 [3].
The colorectal cancer Optimal Care Pathway recommends colonoscopy within four weeks of symptoms presenting [4]. Currently, the system struggles to meet that target. In 2024, only 14.6% of screening participants with a positive result had colonoscopy within 30 days [5]. The median public wait time after a positive screening test is 84 days [4], and many symptomatic patients wait longer [4].
Symptom-based referral finds cancers like Helen’s. It also brings in a much larger group of patients like David, who don’t have cancer. Yet both groups wait in the same queue.
Triage categories depend mostly on the symptoms in the referral letter. Helen’s letter gives you no more reason to act than David’s.
Takeaway: When referral letters look the same, you need objective data to rank patients by risk.
What if you could move Helen forward?
The Gut study also modelled FIT as a triage step [1].
Using a triage threshold of 10 µg haemoglobin per gram of faeces to prioritise symptomatic referrals would move 18% of referrals to the front queue, and avoid 89% of delay-attributable deaths from delayed colonoscopy [1].
The modellers then moved that FIT-positive group to the front of the queue. At four months, delay-attributable deaths fell from 1,419 to 156 [1].
Takeaway: Most of the survival benefit comes from moving the right patients forward. Speeding up the whole list isn’t necessary.
When there’s no FOBT/FIT result
Neither Helen nor David wanted to do a FOBT/FIT. That’s common. Some patients decline stool sampling, and others can’t complete it.
And a completed FOBT/FIT has limits too. It relies on bleeding, and between one in ten and one in eight symptomatic cancers are FIT-negative [6].
Helen’s symptoms still warrant investigation. But without a FOBT/FIT result, you have no objective reason to move her ahead of David.
Takeaway: A second, independent triage signal adds information exactly where FOBT/FIT leaves gaps.
ColoSTAT®: a second signal at referral
Now suppose both GPs ordered ColoSTAT®. It needs only a blood draw, collected like any other standard pathology test.
ColoSTAT® is a blood-based triage test developed from CSIRO research [7]. It measures five protein biomarkers in a single multiplexed ELISA [7]. Testing is performed in a NATA-accredited facility through 4Cyte Pathology [9]. Results arrive in 4–10 working days [9].
GPs order ColoSTAT® for patients symptomatic of bowel cancer aged 45–84. The result goes with the referral.
These figures come from an independent validation cohort of 300 samples from patients aged 45–84 [7]. The cohort included 100 colorectal cancers and 100 advanced adenomas [7].
This is an enriched design, so read the NPV in context. NPV rises as prevalence falls. In the symptomatic pathway, fewer than 4% of colonoscopies find cancer [7]. The 99.4% NPV reflects the real-world prevalence of CRC [9].
Sensitivity stays consistent across stages, with no statistically significant difference between early- and late-stage disease [7]. For a stage II cancer like Helen’s, that consistency matters.
Back to your desk. Helen’s result is a ColoSTAT® positive. David’s is ColoSTAT® negative.
A ColoSTAT® positive result flags higher risk of CRC. With 54.3% specificity, many positives turn out to be benign [7]. But it’s the objective signal Helen’s referral letter lacked. You move her up the list, and her colonoscopy finds the cancer at stage II.
A ColoSTAT® positive result flags higher risk of CRC. With 54.3% specificity, many positives turn out to be benign [7]. But it’s the objective signal Helen’s referral letter lacked. You move her up the list, and her colonoscopy finds the cancer at stage II.
David keeps his place on the list. His ColoSTAT® negative result, safety-netting and clinical follow-up all stay in place. His colonoscopy goes ahead as planned.
Meanwhile, if Helen had received a ColoSTAT® negative — as approximately 1 in 10 cancers will — she would keep her place in the queue and still be scoped.
ColoSTAT® is not a replacement for colonoscopy. Colonoscopy remains the diagnostic standard. ColoSTAT® helps set the order in which patients are seen.
Takeaway: ColoSTAT® gives you objective risk data at referral, when two patients otherwise look the same.
The bottom line
Your list has many patients like David and a few like Helen. Most people referred won’t have cancer.
The priority is to find the Helens, and to find them faster. Waiting lists won’t shrink quickly. Better triage data at referral is available now.
ColoSTAT® gives GPs and gastroenterologists a shared, evidence-based signal for prioritising by risk.
Ask your referring GPs to include a ColoSTAT® result with symptomatic referrals. You can also order it for symptomatic patients already waiting on your list. To find out how to incorporate the test into your practice, contact Rhythm Biosciences below.
Sources
- Loveday C et al. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. Gut. 2021;70:1053–1060.
- Australian Commission on Safety and Quality in Health Care. Atlas Focus Report: Colonoscopy. 2025.
- Cancer Council Australia. Bowel cancer: early detection policy priorities.
- University of Melbourne, Pursuit. Who needs a colonoscopy most? October 2025.
- Bowel Cancer Australia. Colonoscopy wait times. Citing AIHW National Bowel Cancer Screening Program Monitoring Report.
- Jones et al. British Journal of General Practice. 2023;73(731):283–285.
- ColoSTAT® Clinical White Paper. Rhythm Biosciences, April 2026.
- Nair et al., Under Review, 2026.
- Internal data, Rhythm Biosciences, 2025.